Logo (Logo)
Trulicity Injection, Solution
Product Images NDC 0002-1434
49 FDA label images from Eli Lilly And Company · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 49 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 0002-1434). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Qr Code (Qr V1)
Figure (Trulicity Ifu 0point75 Injection Sites V1)
An instructional diagram showing recommended subcutaneous injection sites for Trulicity (Dulaglutide). The highlighted areas in yellow indicate possible injection locations on the front and back of the body, including the abdomen, upper arms, and front and outer sides of the thighs.*
Figure (Trulicity Ifu 1point5 Injection Sites V1)
An instructional diagram showing injection sites on a human figure from front and back views. Highlighted areas for injection include the outer upper arms, abdomen around the navel, and front and back of the thighs.*
Figure (Trulicity Ifu 3mg Injection Sites V1)
Illustration showing recommended injection sites for Trulicity (dulaglutide) on a human figure from front and back views. Darkened areas indicate approved subcutaneous injection locations including the abdomen, outer thighs, and upper arms.*
Figure (Trulicity Ifu 4point5mg Injection Sites V1)
An anatomical illustration showing recommended subcutaneous injection sites for Trulicity (Dulaglutide) on a human body from front and back views. Highlighted areas include the abdomen, front and outer sides of the thighs, and the upper arms.*
Figure (Trulicity Ifu Check V1)
Exclamation (Trulicity Ifu Exclamation V1)
Trulicity injection, solution for subcutaneous use by Eli Lilly and Company, shown in a carton displaying four different strengths: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL. The packaging is white with color-coded labels for each strength.*
Figure (Trulicity Ifu Expiration Location V2)
Trulicity injection pen cap showing an expiration date window. The visible part highlights the expiration date indicator on the pen, which is used for subcutaneous administration of Dulaglutide by Eli Lilly and Company.*
Figure (Trulicity Ifu Inspect V1)
Locked (Trulicity Ifu Locked V1)
Trulicity injection, solution for subcutaneous use in a prefilled pen, available in strengths of 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL. The label displays the proprietary name "Trulicity" with the active ingredient dulaglutide, manufactured by Eli Lilly and Company.*
Figure (Trulicity Ifu Prepare V1)
An instructional illustration depicting a hand under running water with two water droplets falling from above, representing the action of hand washing or rinsing as part of a hygiene or preparation step.*
Figure (Trulicity Ifu Remove V1)
Figure (Trulicity Ifu Sup 0point75 F2 V3)
An instructional illustration showing a hand holding a Trulicity (Dulaglutide) injection pen, poised above a black circular cap held by another hand. A purple arrow indicates the motion of removing or detaching the cap from the injection pen. This diagram is likely part of the usage or preparation instructions for the subcutaneous injection of Trulicity by Eli Lilly and Company.*
Figure (Trulicity Ifu Sup 0point75 F3 V3)
An instructional illustration showing hands preparing a Trulicity (dulaglutide) prefilled injection pen for subcutaneous use. The image highlights the removal of a protective cap or shield from the green-tipped injection device, indicating steps to ready the medication for administration.*
Figure (Trulicity Ifu Sup 0point75 F4 V3)
An instructional illustration showing the technique for administering a subcutaneous injection with the Trulicity injection pen. It depicts a person holding the pen in place on the skin for 5 to 10 seconds after injection and includes a close-up detail of the pen's indicator window to verify completion.*
Figure (Trulicity Ifu Sup 0point75 F5 V3)
An instructional illustration showing a hand holding a pre-filled Trulicity (dulaglutide) injection pen above a sharps disposal container marked with a biohazard symbol, indicating safe needle disposal.*
Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)
An instructional diagram of a Trulicity (Dulaglutide) injection pen illustrating key parts, including the green Injection Button, white Lock Ring, Indicator, Lock/Unlock symbols, the Medicine chamber, Clear Base, and Base Cap at the bottom/needle end. The pen is oriented with the top at the Injection Button and the bottom at the needle end.*
Figure (Trulicity Ifu Sup 0point75 Pen V3)
Trulicity injection pen containing Dulaglutide solution for subcutaneous use. The pen label features purple, yellow, and white colors with dosing indicator windows, and the cap is green. The product is manufactured by Eli Lilly and Company.*
Figure (Trulicity Ifu Sup 1point5 F2 V3)
An instructional diagram showing a hand holding a Trulicity injection pen (solution for subcutaneous injection). The illustration indicates removal of a black cap from the pen, with a downward arrow highlighting the direction to pull the cap off, likely as part of the injection preparation process.*
Figure (Trulicity Ifu Sup 1point5 F3 V3)
An instructional diagram showing a person preparing a Trulicity injection device for subcutaneous administration. The hands are holding the pen injector with an arrow indicating the removal of a protective cap before injection, suggesting the step to unlock or prepare the device for use.*
Figure (Trulicity Ifu Sup 1point5 F4 V3)
An instructional illustration showing a person holding a Trulicity injection pen, demonstrating how to press and hold the pen against the skin for 5 to 10 seconds. A close-up inset highlights the pen's needle area during injection. This visual guides proper subcutaneous administration technique for Trulicity (dulaglutide) injection solution.*
Figure (Trulicity Ifu Sup 1point5 F5 V3)
An instructional illustration showing a hand holding a prefilled syringe for subcutaneous injection, positioned above a sharps disposal container marked with a biohazard symbol. The image relates to the safe disposal of used injection devices, relevant to Trulicity (dulaglutide) injection, solution, offered by Eli Lilly and Company.*
Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)
An illustration diagram of a Trulicity (dulaglutide) injection pen labeled with parts including Injection Button, Lock Ring, Indicator, Lock/Unlock symbols, Medicine chamber, Clear Base, and Base Cap. Directions indicating the Top and Bottom/Needle End are also shown.*
Figure (Trulicity Ifu Sup 1point5 Pen V3)
Trulicity injection, solution in a single-dose, pre-filled pen injector. The device is primarily white with a blue and purple design panel and a green dose button at the end. The pen is designed for subcutaneous administration and labeled by Eli Lilly and Company.*
Figure (Trulicity Ifu Sup 3mg F2 V1)
An instructional illustration showing hands manipulating a Trulicity injection pen and its needle cap. The image demonstrates holding the injection pen with one hand and removing the needle cap with the other, indicated by a downward arrow, outlined with a red border and a lock icon.*
Figure (Trulicity Ifu Sup 3mg F3 V1)
An instructional illustration showing hands preparing a Trulicity (Dulaglutide) injection device for subcutaneous administration. The image depicts twisting or unlocking the green cap of the injection pen prior to use.*
Figure (Trulicity Ifu Sup 3mg F4 V1)
Illustration depicting the subcutaneous injection technique for Trulicity (Dulaglutide) injection, solution. It shows a hand holding the injection pen against the thigh, indicating to hold for 5-10 seconds. A close-up inset highlights the gray plunger becoming visible as confirmation that the injection is complete.*
Figure (Trulicity Ifu Sup 3mg F5 V1)
Illustration showing a hand holding a prefilled Dulaglutide injection pen above a biohazard sharps container, demonstrating safe disposal of the injectable pen after use.*
Figure (Trulicity Ifu Sup 3mg Pen Parts V1)
An instructional diagram of a Trulicity injection pen identifying its key components. Labeled parts include the Injection Button, Lock Ring, Indicator, Lock/Unlock mechanism, Medicine reservoir, Clear Base, and Base Cap at the needle end.*
Figure (Trulicity Ifu Sup 3mg Pen V1)
Trulicity injection pen device for subcutaneous use, containing Dulaglutide. The pen is primarily white with a green end cap and a clear section showing the injection mechanism. It features a purple and blue label band with small red and green indicator symbols, consistent with a prefilled injectable solution by Eli Lilly and Company.*
Figure (Trulicity Ifu Sup 4point5 F2 V1)
An instructional illustration showing how to administer Trulicity (Dulaglutide) injection. It depicts a hand holding the autoinjector pen and another hand removing or preparing a component, with a purple arrow indicating downward movement, likely demonstrating the injection step or preparation of the injection device.*
Figure (Trulicity Ifu Sup 4point5 F3 V1)
An instructional illustration showing hands preparing a Trulicity (dulaglutide) injection device for subcutaneous use. The image demonstrates the step of twisting the green cap off the autoinjector prior to injection.*
Figure (Trulicity Ifu Sup 4point5 F4 V1)
An instructional diagram illustrating the correct technique to use the Trulicity injection pen. It shows a hand holding the pen against the skin, pressing the injection button for 5-10 seconds. A magnified view highlights the gray plunger, indicating that the injection is complete when the gray plunger is visible.*
Figure (Trulicity Ifu Sup 4point5 F5 V1)
An instructional illustration showing a hand holding a syringe above a biohazard sharps disposal container. The image emphasizes proper disposal of used syringes in a designated biohazard container.*
Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)
Illustration of a Trulicity (Dulaglutide) injection pen showing labeled parts: Injection Button at the top, Lock Ring below it, Indicator and Lock/Unlock symbols on the body, Medicine section visible through the Clear Base, with the Base Cap at the bottom which is the needle end.*
Figure (Trulicity Ifu Sup 4point5 Pen V1)
Trulicity injection pen device for subcutaneous use, containing dulaglutide. The pen features a clear medication window, a gray cap at one end, and purple, white, and green coloring on the body. It is manufactured by Eli Lilly and Company and available in multiple strengths including 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, and 4.5 mg/0.5 mL.*
Figure (Trulicity Ifu Unfold V1)
Instructional diagram illustrating how to unfold an informational leaflet. The image directs consumers to unfold the leaflet flat and read both sides for complete instructions. This type of diagram commonly accompanies medication packaging to guide users on accessing detailed information.*
Unlocked (Trulicity Ifu Unlock V1)
Trulicity injection, solution prefilled pen label for subcutaneous use, showing dosage strength of 4.5 mg per 0.5 mL. The label includes storage instructions, a lot number, expiration date, and manufacturer information, Eli Lilly and Company.*
Figure 1 (Trulicity Pi F1 V2)
A forest plot chart depicting pharmacokinetic (PK) parameters AUC and Cmax ratios with 90% confidence intervals relative to reference for Trulicity (Dulaglutide). It compares intrinsic factors including weight, age, gender, race, renal impairment, and hepatic impairment, showing their effect on drug exposure ratios.*
Figure 2 (Trulicity Pi F2 V2)
A chart showing pharmacokinetic ratios and 90% confidence intervals (CI) for various coadministered drugs relative to a reference. The chart lists drugs on the left including Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin, with parameters AUC and Cmax. The x-axis shows the ratio relative to reference, ranging from 0.0 to 2.0, with data points represented as diamond shapes with error bars for each drug and parameter.*
Figure 3 (Trulicity Pi F3 V1)
A line graph showing the least squares mean HbA1c percentage over 52 weeks post-randomization for treatments including Trulicity 0.75 mg, Trulicity 1.5 mg, Sitagliptin 100 mg, and placebo. The x-axis represents weeks from 0 to 52, and the y-axis shows HbA1c (%) from approximately 6.6 to 8.4. Data points illustrate changes in HbA1c with Trulicity doses showing greater reduction compared to Sitagliptin and placebo.*
Figure 5 (Trulicity Pi F4 V1)
A line graph showing the mean HbA1c percentage over 26 weeks post-randomization for Trulicity injection solution at 0.75 mg and 1.5 mg doses, Exenatide, and placebo. The graph includes data points at baseline, week 13, and week 26, with mean HbA1c decreasing most in the Trulicity 1.5 mg group. The number of subjects observed is reported for each group at weeks 0 and 26.*
Figure 6 (Trulicity Pi F5 V1)
A line graph comparing the percentage of patients with an event over time (years) from randomization for Dulaglutide versus placebo. The graph shows Dulaglutide with a slightly lower event rate than placebo over approximately 6 years, including a hazard ratio (HR) of 0.88 with a 95% confidence interval of 0.79 to 0.99. Patient numbers at risk are listed below the x-axis for both groups at various time points.*
Figure 4 (Trulicity Pi F6 V1)
A line graph showing mean HbA1c (%) over weeks post-randomization for Trulicity injection solution at 1.5 mg, 3 mg, and 4.5 mg doses. The x-axis represents weeks from baseline to 36 weeks, and the y-axis shows mean HbA1c percentage, illustrating a decline and stabilization over time for all three dosage groups. The chart includes data points and sample sizes for each dose group at initial and later time points.*
Us Trulicity Sup 1point5mg 005 04
Trulicity (dulaglutide) injection 1.5 mg/0.5 mL single-dose pens packaging label by Eli Lilly and Company. The carton contains 4 single-dose pens for subcutaneous injection, with instructions to use one pen weekly. The design features purple, blue, and white colors with the Lilly logo and website www.trulicity.com.*
Package Label – Trulicity™, 3 mg/0.5 mL, Prefilled Pen, 4 Count (Us Trulicity Sup 3mg 055 01)
Trulicity 3 mg/0.5 mL injection solution in single-dose pens, a subcutaneous human prescription drug by Eli Lilly and Company. The packaging box contains 4 single-dose pens, each delivering a 3 mg dose, for once weekly use. The label includes the product name, active ingredient dulaglutide, dosage strength, administration route, and manufacturer information, along with usage instructions and Rx-only designation.*
Package Label – Trulicity™, 4.5 mg/0.5 mL, Prefilled Pen, 4 Count (Us Trulicity Sup 4point5mg 056 01)
Trulicity (dulaglutide) injection 4.5 mg/0.5 mL single-dose pens carton, showing packaging for four pens. The label indicates it is a subcutaneous injection, once weekly dose, and includes usage instructions and the Eli Lilly and Company logo. The carton design features purple and green accents.*
Us Trulicity Sup Point75mg 004 04
Packaging label for Trulicity 0.75 mg/0.5 mL injection, a subcutaneous solution containing dulaglutide. The label shows a 4-count pack of single-dose pens, with each pen delivering a 0.75 mg dose for once-weekly use. The labeler is Eli Lilly and Company, and the packaging features purple, white, green, and yellow design elements with the Trulicity pen image.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
